In March 2016, Li and others were suspected of the crime of illegally manufacturing and selling illegally manufactured invoices. A Chongqing pharmaceutical Co., Ltd. had previously purchased fake invoices from Li and others to defraud bank loans. The chairman of the company was afraid that the matter would be exposed, so he arranged for Hu, the vice president of the company, to trust the relationship to solve the problem.
According to the investigation, Zhou accepted Hus bribes of 1.6 million yuan in six times from May 2016 to September 2017, and gave more than 1 million yuan to his father to buy a house for him, and the rest was used for daily expenses.
In the judicial documents, there was also a fraud case involving a total amount of 40 billion yuan, and the protagonist of the case was a pharmaceutical company in Chongqing.
According to the judgment document, in July 2018, Chongqing Public Security Bureau found that a pharmaceutical company in Chongqing had taken the form of receivables pledge to lend loans to more than a dozen banks such as Hankou, Minsheng, Everbright and CITIC. After the tax authorities screened the VAT invoices provided by the company, it was found that the invoice did not have the seal of the State Administration of Taxation, and the face value of the invoice was in line with the tax The actual amount in the system is inconsistent, and the invoice is suspected to be forged.
The investigation found that a pharmaceutical company in Chongqing used forged invoices to loan to several banks, which was suspected of loan fraud.
In the investigation and handling of the fraud loan case, the police also found that Li, the chairman of the company, fraudulently obtained 24.3 billion yuan of financing funds from Huaye capital and other financial institutions by forging the accounts receivable and creditors rights held by the company to the first, second and third affiliated hospitals of the army Military Medical University to Beijing Huaye Capital Holding Co., Ltd Suspected contract fraud crime.
On July 9 and October 12, 2018, Chongqing Public Security Bureau filed a case of a pharmaceutical company in Chongqing suspected of obtaining loans and contract fraud. After the investigation, Chongqing Public Security Bureau transferred the case to the procuratorial organ for examination and prosecution.
On December 31, 2019, the fifth branch of Chongqing Municipal Peoples Procuratorate sued the fifth intermediate peoples Court of Chongqing, accusing a pharmaceutical company in Chongqing, Li Mou and others of defrauding loans of 14.25877 billion yuan from ten banks including Chongqing Everbright Bank, 1.819 billion yuan of acceptance bills, 24.204 billion yuan of contract fraud, and bribery of non-state staff, which constituted the crime of obtaining loans and financial certificates Crime of contract fraud, bribery of non state staff.
In other words, according to the charges, a pharmaceutical company in Chongqing is suspected of fraud of nearly 40 billion yuan.
Listed companies will never recover due to fraud
Huaye capital used to be a star enterprise in the capital market. Originally, it mainly engaged in real estate, and then transformed into debt investment, mainly investing in the accounts receivable of medical institutions.
Specifically, the operation mode of medical financial supply chain business is to purchase the accounts receivable generated by the suppliers providing drugs, equipment, consumables, etc. by purchasing suppliers with asset management plan, partnership enterprise, trust plan and other financial products at a discount price, the top three hospitals will return the funds according to the original value of the accounts receivable on the due date, so as to realize the investment income.
At first, this financial business brought great benefits to the company: in 2017, the income was 615 million yuan, accounting for 61.62% of the net profit of that year; in the first half of 2018, the income again reached 415 million yuan, accounting for 42.3% of the net profit.
However, the good times are not long. After two years of good life, this once money tree has become the fuse for the capital of Huaye to withdraw from the market.
At the beginning, the creditors rights of accounts receivable invested by the subsidiary Tibet Huashuo Investment Co., Ltd. were overdue, with a total overdue amount of 888 million yuan. After that, when Huaye capital sent lawyers to the first, second and third affiliated hospitals of the debtors Army Military Medical University to understand the situation, and then found that the debt agreement was false and the official seal on the document was forged!
What is intriguing is that the actual controller of Hengyun medicine is Li or the second shareholder of Huaye capital.
The 10 billion accounts receivable can not be recovered, and the nightmare of Huaye capital begins: the capital chain is broken, the debt is heavy, the annual report of 2018 is non-standard, the listed companies are wearing the hat, and the stock price is plummeting
From October 16 to November 12, 2019, the closing prices of * ST Huaye for 20 consecutive trading days were lower than the par value of RMB 1, which touched the delisting situation stipulated by the exchange, and the trading of the companys shares was suspended from November 13.
Mysterious two shareholders of Huaye capital
The 10 billion radish chapter scam points to a key figure, Li Shilin, the second shareholder of Huaye capital and the actual controller of Hengyun pharmaceutical.
In 2015, Huaye capital acquired 100% equity of Chongqing Jieer controlled by Li and his younger brother for 2.15 billion yuan.
In 2016, the former major shareholder of Huaye capital transferred 218 million shares (15.33% share ratio) to several companies under Li, and Li Shilin became the second shareholder of Huaye capital.
It is worth noting that among the enterprises under the name of Li Shilin, Hengyun pharmaceutical mainly deals in medical devices, and its business is mainly to supply various high-end and low-end equipment consumables in various departments of several Grade-A comprehensive general hospitals, and has been operating medical financial business in Chongqing market for many years.
After that, the creditors rights of Hengyun pharmaceutical became the quota target of Huaye capital entering the medical financial market. The two sides finally agreed that the financial creditors rights of the third class a hospital of 10.189 billion yuan was transferred to Huaye capital at a discount by Li. Under the good news, the stock price of Huaye capital was once high.
In the reply announcement of the annual report of 2018 and the inquiry letter of performance in advance in 2018, * ST Huaye said that after the acquisition of Jieer medical in 2015, Jieer medical and its subsidiaries have repeatedly provided guarantees for Li Shilin, Hengyun pharmaceutical and other related parties. During the reporting period, 9 cases were involved, involving an amount of 1.713 billion yuan, accounting for 25.18% of the companys net assets at the end of 2017.
On November 25, 2019, the Shanghai Stock Exchange said that Li Shilin, as the second largest indirect shareholder of the company, took advantage of his indirect shareholding position to carry out a huge amount of debt investment related transactions with the company. However, the relevant creditors rights transferred by the controlled enterprise to the company were not true to the underlying debt, resulting in huge economic losses of the company. As the second largest indirect shareholder of * ST Huaye, Li Shilin was publicly denounced by the exchange and banned from serving as a director, supervisor and senior manager of a listed company for life. Prior to this, on June 21, 2019, * ST Huaye released a notice on the progress of the companys litigation cases. Li Shilin, the second largest shareholder of the company, was arrested, and Li JinFang, the actual controller of the contract fraud case of Chongqing Hengyun Pharmaceutical Co., Ltd., was prosecuted. Source: Yang Qian, editor in charge of China fund daily_ NF4425
On November 25, 2019, the Shanghai Stock Exchange said that Li Shilin, as the second largest indirect shareholder of the company, took advantage of his indirect shareholding position to carry out a huge amount of debt investment related transactions with the company. However, the relevant creditors rights transferred by the controlled enterprise to the company were not true to the underlying debt, resulting in huge economic losses of the company.
As the second largest indirect shareholder of * ST Huaye, Li Shilin was publicly denounced by the exchange and banned from serving as a director, supervisor and senior manager of a listed company for life.
Prior to this, on June 21, 2019, * ST Huaye released a notice on the progress of the companys litigation cases. Li Shilin, the second largest shareholder of the company, was arrested, and Li JinFang, the actual controller of the contract fraud case of Chongqing Hengyun Pharmaceutical Co., Ltd., was prosecuted.